Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Tony Reiman, MD, Daygen Finch, MD, Neil Chua, MD, Darrell White, MD, Douglas A. Stewart, MD, Richard van der Jagt, MD, James Johnston, MD, Angeli Prasad, Henry Schwarz, Jerome Zeldis, MD, Andrew R. Belch, MD

Blood (2007) 110 (11): 2579.

https://doi.org/10.1182/blood.V110.11.2579.2579

Published: 2007

Journal Articles

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

Edward Stadtmauer, MD, Donna Weber, MD, M. Dimopolous, MD, Andrew Belch, MD, Michel Attal, MD, Miles Prince, MD, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, MD, Robert Knight, MD

Blood (2006) 108 (11): 3552.

https://doi.org/10.1182/blood.V108.11.3552.3552

Published: 2006

Journal Articles

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Michael Wang, MD, Robert Knight, MD, Melitios Dimopoulos, MD, David Siegel, MD, S. Vincent Rajkumar, MD, Thierry Facon, MD, Raymond Alexanian, MD, Zhinuan Yu, PhD, Jerome Zeldis, MD, PhD, Marta Olesnyckyj, Donna Weber, MD

Blood (2006) 108 (11): 3553.

https://doi.org/10.1182/blood.V108.11.3553.3553

Published: 2006

Journal Articles

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

Asher Alban Chanan-Khan, MD, Zhinuan Yu, PhD, Donna Weber, MD, Christine Chen, MD, Ruben Niesvizky, MD, Andrew Spencer, MD, Michel Attal, MD, Andrew Belch, MD, Miles Prince, MD, Marta Olesnyckyj, Robert Knight, MD, Jerome Zeldis, MD, Meletius Dimopoulos, MD

Blood (2006) 108 (11): 3554.

https://doi.org/10.1182/blood.V108.11.3554.3554

Published: 2006

Journal Articles

Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.

Donna E. Reece, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Lisa Wang, Saima Dean, Vishal Kukreti, MD, Joseph R. Mikhael, MD, Suzanne Trudel, MD, Robert Knight, MD, Jerome Zeldis, MD

Blood (2006) 108 (11): 3548.

https://doi.org/10.1182/blood.V108.11.3548.3548

Published: 2006

Journal Articles

Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma.

Donna E. Reece, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Lisa Wang, Saima Dean, Suzanne Trudel, MD, Joseph R. Mikhael, MD, Vishal Kukreti, MD, Robert Knight, MD, Jerome Zeldis, MD

Blood (2006) 108 (11): 3550.

https://doi.org/10.1182/blood.V108.11.3550.3550

Published: 2006

Journal Articles

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide (TPC Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Ruben A. Mesa, MD, Animesh Pardanani, MD, PhD, David P. Steensma, MD, Mark Litzow, MD, William Hogan, MD, Susan Geyer, PhD, Wenting Wu, PhD, Jerome Zeldis, MD, PhD, Ayalew Tefferi, MD

Blood (2006) 108 (11): 2689.

https://doi.org/10.1182/blood.V108.11.2689.2689

Published: 2006

Journal Articles

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

Antonio Palumbo, MD, Patrizia Falco, MD, Antonietta Falcone, MD, Paolo Corradini, MD, Francesco Di Raimondo, MD, Nicola Giuliani, MD, Giuseppe Rossi, MD, Fortunato Morabito, MD, Letizia Canepa, MD, Alessandro Gozzetti, MD, Maria Teresa Ambrosini, MD, Jerome Zeldis, MD, Robert Knight, MD, Robin Foà, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2006) 108 (11): 800.

https://doi.org/10.1182/blood.V108.11.800.800

Published: 2006

Journal Articles

Reversal of Myelofibrosis in a Patient with Low Risk Myelodysplastic Syndrome on Revlimid Therapy.

Emmanuel C. Besa, MD, Vanlila Swami, MD, Paul Roda, M.D, Mary Ann Laudadio, R.N., Robert Knight, MD, Jerome Zeldis, MD

Blood (2005) 106 (11): 4908.

https://doi.org/10.1182/blood.V106.11.4908.4908

Published: 2005

Journal Articles

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

Meletios A. Dimopoulos, MD, Andrew Spencer, MBBS, Michael Attal, MD, PRD, Miles Prince, MD, Jean-Luc Harousseau, MD, Anna Dmoszynska, MD, PhD, Zhinuan Yu, PhD, Marta Olesnyckyj, RN, BSN, Jerome Zeldis, MD, Robert Knight, MD

Blood (2005) 106 (11): 6.

https://doi.org/10.1182/blood.V106.11.6.6

Published: 2005

Journal Articles

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Paul Richardson, MD, Sundar Jagannath, MD, Mohamad Hussein, MD, James Berenson, MD, Seema Singhal, MD, David Irwin, MD, Stephanie F. Williams, MD, William Bensinger, MD, Ashraf Z. Badros, MD, Robert Vescio, MD, Laurie Kenvin, BSN, Zhinuan Yu, PhD, Marta Olesnyckyj, RN, BSN, Herbert Faleck, DO, Jerome Zeldis, MD, Robert Knight, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 1565.

https://doi.org/10.1182/blood.V106.11.1565.1565

Published: 2005

Journal Articles

Oral Revlimid R Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.

Antonio Palumbo, MD, Patrizia Falco, MD, Pellegrino Musto, MD, Paolo Corradini, MD, Francesco Di Raimondo, MD, Giuseppe Rossi, MD, Nicola Giuliani, MD, Fortunato Morabito, MD, Annalisa Luraschi, MD, Antonietta Falcone, MD, Paola Omedè, PhD, Francesca Gay, MD, Ilaria Avonto, MD, Maria Teresa Ambrosini, MD, Sara Bringhen, MD, Jerome Zeldis, MD, Robert Knight, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2005) 106 (11): 785.

https://doi.org/10.1182/blood.V106.11.785.785

Published: 2005

Journal Articles

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Mohamad A. Hussein, MD, Mary Ann Karam, RN, Catherine Brand, Greg L. Pearce, Janice Reed, RN, Kellie Bruening, Paul Sartori, Gordan Srkalovic, MD, PhD, Marta Olesnyckyj, RN, Robert Knight, MD, Kathe Balinski, RN, MA, Jerome Zeldis, MD, PhD

Blood (2004) 104 (11): 208.

https://doi.org/10.1182/blood.V104.11.208.208

Published: 2004

NARROW

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.

Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma.

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide (TPC Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

Reversal of Myelofibrosis in a Patient with Low Risk Myelodysplastic Syndrome on Revlimid Therapy.

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Oral Revlimid R Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only